Trialect

Active

Notice of Special Interest (NOSI): Advancing Genomic Technology Development for Research and Clinical Application

National Institutes of Health

The National Human Genome Research Institute (NHGRI) is issuing this Notice of Special Interest (NOSI) to encourage applications focused on developing novel laboratory-focused tools and technologies that enable new lines of scientific inquiry and advance research or clinical applications in human genomics.

The field of genomics has repeatedly benefited from the development of new methodologies and substantial advances in genomic technologies. NHGRI seeks applications for genomic technology development research that would, if successful, have an impact in a three to seven-year time frame to move the field of genomics beyond the likely next steps in technological advances. It is expected that applicants will develop scientific and practical definitions of optimal cost, quality, bio-materials quantity, scale, time to result and other important features enabling the significant genomics technology development proposed. Ultimately these technologies should have the capability to be used in a high-throughput, production setting to generate high-quality data. Priority will be given to applications that propose improvements of at least an order of magnitude (based on state of the art at the time the application is submitted). Such improvements may be achieved by focusing on one critical factor or a combination of important ones.

Many proposals will benefit from computational elements planned as part of a well-integrated technology development effort. Co-development of methods for analysis of the new or improved data types generated can maximize usefulness and derive additional information content. However, work predominantly focused on computational approaches alone is beyond the focus of this notice for genomic technology development and may be more appropriate for other calls like Investigator Initiated Research in Computational Genomics and Data Science ( R01 Clinical Trial Not Allowed along with the related R21 ).

This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through January 10, 2027.

NOT-HG-24-012